BioCryst Pharmaceuticals, Inc. (BCRX) Financials
BCRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 517.0 million | 972.5 million |
2023-09-30 | -685.5 million | 933.9 million |
2023-06-30 | 529.9 million | 918.6 million |
2023-03-31 | 509.7 million | 838.0 million |
BCRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -9.5 million | 16.5 million |
2023-09-30 | -20.9 million | 12.3 million |
2023-06-30 | -19.3 million | 12.8 million |
2023-03-31 | -47.7 million | 14.0 million |
BCRX Net Income
No data available :(
BCRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 390.8 million | - | 13.9 million |
2023-09-30 | 397.6 million | - | 12.2 million |
2023-06-30 | 414.1 million | 293.2 million | 8.3 million |
2023-03-31 | 401.6 million | 232.5 million | 8.4 million |
BCRX Shares Outstanding
BCRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 554000 | 69.6 million | 64.4 million | - |
2023-09-30 | 987000 | 46.9 million | 50.6 million | - |
2023-06-30 | 467000 | 51.2 million | 47.7 million | 3.3 million |
2023-03-31 | 160000 | 48.4 million | 43.8 million | 4.0 million |
BCRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 93.4 million | 2.1 million |
2023-09-30 | 86.7 million | 1.1 million |
2023-06-30 | 82.5 million | 950000 |
2023-03-31 | 68.8 million | 938000 |
BCRX
Price: $4.16
52 week price:
Earnings Per Share: -1.18 USD
P/E Ratio: -4.06
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.7 million
Ebitda: -12.8 millionMarket Capitalization: 948.3 million